Cardinal Health (CAH)
(Delayed Data from NYSE)
$113.28 USD
+0.11 (0.10%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $113.27 -0.01 (-0.01%) 6:08 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$113.28 USD
+0.11 (0.10%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $113.27 -0.01 (-0.01%) 6:08 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Zacks News
Cardinal Health (CAH) Buys Specialty Networks to Boost Workflow
by Zacks Equity Research
Cardinal Health (CAH) acquires Specialty Network to technologically strengthen its specialty therapeutic areas. The acquisition also supports the company's ongoing Navista Network.
Jobless Claims & Productivity Leap Higher; CAH, IP, HON Report
by Mark Vickery
Once the market closes, we'll await earnings reports from three of the Magnificent 7 stocks: Apple, Amazon and Meta.
Cardinal Health (CAH) Beats on Q2 Earnings, Ups '24 EPS View
by Zacks Equity Research
Cardinal Health's (CAH) second-quarter fiscal 2024 results benefit from the Pharmaceutical segment's solid performance.
Should Value Investors Buy Cardinal Health (CAH) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Compared to Estimates, Cardinal (CAH) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Cardinal (CAH) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Cardinal Health, Inc. (CAH) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Cardinal (CAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks.com featured highlights include Axonics, Enerpac Tool Group, Cardinal Health and Acuity Brands
by Zacks Equity Research
Axonics, Enerpac Tool Group, Cardinal Health and Acuity Brands are part of the Zacks Screen of the Week article.
Cardinal Health and RH have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Cardinal Health and RH are part of the Zacks Bull and Bear of the Day article.
Cardinal Health (CAH) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Cardinal (CAH) delivered earnings and revenue surprises of 16.67% and 1.10%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Align Technology (ALGN) Q4 Revenues Top, Margins Expand
by Zacks Equity Research
Align Technology (ALGN) surpasses revenue and earnings estimates in the fourth quarter of fiscal 2023.
Bull of the Day: Cardinal Health (CAH)
by Ethan Feller
Cardinal Health enjoys a top Zacks rank and impressive EPS growth forecasts at a fair price
Medical Device Stocks' Earnings on Feb 1: RVTY, CAH & More
by Debanjana Dey
Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how CAH, RVTY, CNMD, SRDX and BDX are placed ahead of their earnings releases.
Are Medical Stocks Lagging Cardinal Health (CAH) This Year?
by Zacks Equity Research
Here is how Cardinal Health (CAH) and CSL Limited Sponsored ADR (CSLLY) have performed compared to their sector so far this year.
4 Stocks Backed by High Efficiency to Enrich Your Portfolio
by Santanu Roy
Invest in companies like Axonics (AXNX), Enerpac Tool Group (EPAC), Cardinal Health (CAH) and Acuity Brands (AYI) due to higher efficiency levels.
What's in Store for Cardinal Health (CAH) in Q2 Earnings?
by Zacks Equity Research
Cardinal Health's (CAH) second-quarter fiscal 2024 results are expected to reflect solid performance in the Pharmaceutical segment.
Ahead of Cardinal (CAH) Q2 Earnings: Get Ready With Wall Street Estimates for Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of Cardinal (CAH) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Cardinal (CAH) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Cardinal (CAH) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Intuitive Surgical (ISRG) Q4 Earnings Beat, Procedures Robust
by Zacks Equity Research
Intuitive Surgical's (ISRG) fourth-quarter results reflect healthy demand for procedures, partially offset by lower system sales. Higher pricing boosts procedure sales.
Cardinal Health (CAH) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Cardinal (CAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
5 Low Leverage Stocks to Buy on Expectations of Rate Cuts
by Aparajita Dutta
The crux of safe investment lies in choosing a company that is not burdened with debt, as a debt-free stock is almost impossible to find. You may buy NSIT, ACA, CAH, PLAB and WING.
Reasons to Add Merit Medical (MMSI) to Your Portfolio Now
by Zacks Equity Research
Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.
Reasons to Retain Inari Medical (NARI) in Your Portfolio Now
by Zacks Equity Research
Inari Medical (NARI) continues to benefit from its commitment to understanding the venous system. However, its dependency on the adoption of products is a concern.
Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FXH